Selective inhibitors of BAFF and APRIL, which should ameliorate the pathogenesis by inhibiting autoreactive B cell activation and autoantibody production, are in clinical trials for autoimmune diseases (Fig. 1). Here, TNFSF13 is linked to autoimmune disease.